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Objectives: 
After completion of this program, the reader should be able to: 
1. Identify ways in which Antimicrobial Stewardship Programs (ASPs} are utilized to decrease microbial resistance. 
2. Comprehend the multiple and interconnected roles of various health care professionals associated with ASPs. 
3. Recognize the significant decrease in current research and development of antimicrobial agents by major pharmaceutical 
companies and its impact on the need to properly utilize available antibiotics. 
4. List strategies that can be established to create and run an effective institutional ASP. 
5. Examine how the quality of patient health has been improved as a result of successful implementation of ASPs in a variety of 
health care settings. 
Abstract 
Antimicrobial Stewardship Programs (ASPs} are becoming in-
creasingly prevalent in the United States as concerns continue to 
mount regarding antimicrobial resistance and the lack of new, 
novel antibiotics being introduced. There are a multitude of fac-
tors that have contributed to the escalation in antimicrobial re-
sistance, with some of the more common concerns being overly 
broad antimicrobial coverage and prolonged antimicrobial treat-
ASPs have had unparalleled success 
in achieving their goals due to the 
collaboration of health care personnel, 
informatics, data collection, and 
ment amongst others. While antimicrobial resistance is a prob- effective policies being employed. 
lem of international proportion, each hea Ith care institution re- j_ _______ _____ _____ ·-· ____ ____ _____ _ __ ___ ___ _ _ _____ _____ _________ __ 1 
mains responsible for assessing its own protocols pertinent to 
antimicrobial usage. ASPs have had unparalleled success in achieving their goals due to the collaboration of health care personnel, 
informatics, data collection, and effective policies being employed. While the pharmaceutical industry struggles with the develop-
ment of novel antimicrobials, ASPs are a critical component to promote the continued efficacy of currently available antimicrobials. 
A considerable number of strategies have been established to implement and manage an effective institutional ASP, including 
educational programs, the development of institutional antimicrobial and disease state guidelines, prior approval for certain broad-
spectrum agents, post-prescription review, and computer-based decision support. However, resources are often limited thus 
creating barriers for institutional ASP success. Some common barriers include a lack of fundraising, inadequate or absent diagnostic 
facilities, poor data collection, variation in data collection, a lack of communication among various health care professionals and a 
lack of cooperation among health care facilities. 
ASPs have the potential to reduce antimicrobial resistance evolution and therefore improve patient outcomes. The involvement of 
multiple health care professionals, including pharmacists, is imperative to the success of an ASP. 
Introduction 
Inappropriate prescribing, overuse of antimicrobial agents and even appropriate antibacterial use have resulted in multidrug-
resistant organisms, elevated medical care costs and adverse events. 1 On a universal level, there is a growing concern of increased 
antimicrobial resistance which has led to the development of ASPs. An ASP is defined by the Infectious Diseases Society of America 
(IDSA) and Society for Healthcare Epidemiology of America (SHEA) as "a system of personnel, informatics, data collection, and pol-
icy/procedures that promotes the optimal selection, dosing, and duration of therapy for antimicrobial agents throughout the 
course of their use."2 Furthermore, the World Health Organization (WHO) defines optimal antibiotic prescriptions as "the cost-
effective use of antimicrobials which maximizes their clinical therapeutic effect, while minimizing both drug-related toxicity and the 
development of antimicrobial resistance." 3 As seen by the definitions of ASPs and optimal prescriptions, preventing antimicrobial 
resistance truly involves all sections of health care, especially pharmacy. 
Nonetheless, there exists a significant 
gap between the presence of novel 
candidates in the latter stages of the 
"US drug-development pipeline" and 
the increasing number of resistant 
microorganism strains. 
Impetus for the Development of ASPs 
Pharmaceutical advancements in drug development of novel an-
timicrobials have been steadily declining. The number of new anti-
bacterial drugs approved for marketing in the United States con-
tinues to decrease7 (Figure 1). It is important to recognize that it 
is not only the number of antimicrobials in the drug-development 
pipeline, or the number of antimicrobials that have been recently 
approved, but also the quality of novel drugs developed with new 
mechanisms of action. 
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Figure 1. New antibacterial agents approved in the US, 1983-2007, per 5-year period5'6'7 
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The decrease in research and development for antimicrobial agents by major pharmaceutical companies has not gone unnoticed, 
and is highlighted when current treatment options become susceptible to resistant microorganisms. The IDSA and the Antimicro-
bial Availability Task Force (AATF) have expressed concern over this issue. 4 Nonetheless, there exists a significant gap between the 
presence of novel candidates in the latter stages of the "US drug-development pipeline"4 and the increasing number of r~c;istant 
microorganism strains. For example, the quantity of ~-lactamases has greatly increased-in 1970, there were 13 of these enzymes 
known, 282 in 1999, and 532 in 2004.4 
The Role of ASPS 
Approximately 60 percent of hospitalized patients in the United 
States receive at least one dose of an antimicrobial agent. In 2002, 
there were approximately 1.7 million health care-associated infec-
tions (HAis) in the United States, which resulted in about 98,987 
fatalities. Many of the HAis were caused by pathogens resistant to 
antimicrobial agents.2 Alarmingly, more people now die of MRSA 
"More people now die of MRSA 
infection in U.S. hospitals than of 
HIV/ AIDS and tuberculosis combined." 
infection in U.S. hospitals than of HIV/AIDS and tuberculosis com- -======================::!..J 
bined.5 Additionally, many of the therapeutic options for these pathogens are limited, sometimes forcing prescribers to use older 
drugs often associated with increased risk of toxicity. Furthermore, the number of elderly patients, individuals undergoing surgery, 
transplantation, and other procedures continues to increase making the average patient more susceptible to these infections due 
to their immunocompromised status.5 
As it becomes clear that antimicrobial resistance is an increasingly troublesome reality, the roles of ASPs today become ever more 
significant in the health care world . The primary goal of ASPs is to increase the quality of patient care, while the secondary goal in-
volves reducing health care costs.2 Additionally, ASPs are aimed at being able to successfully use current antimicrobial agents in the 
future by limiting overuse and misuse of antimicrobials today, thus minimizing antimicrobial resistance. 1 The use of ASPs can de-
crease medication errors pertaining to antimicrobials, such as preventing duplicate antimicrobials or avoiding the prescribing of un-
needed antimicrobials.8 Ultimately, infections that arise from multidrug-resistant (MDR) pathogens increase the length of illness and 
hospital stays.9 Efficient ASPs should monitor the proportions of antimicrobial agents used in patient populations to ensure there is 
some diversity in the prescribed drugs for specific indications. This monitoring will aid in avoiding the development of resistance to 
antibiotic classes as a whole. 1 Additionally, ASPs encourage the streamlining or the de-escalating of therapy in the earliest possible 
stages of a treatment, the transfer to oral treatment from parenteral treatment, the administration of antimicrobial agents over the 
correct length of time and the administration of the correct dose. In many institutions without ASPs, the ability to tailor a medication 
regimen from the initial broad-spectrum therapy is neglected even when microbiologic data becomes available. Similarly, "spiraling 
empiricism" occurs when broad-spectrum antibiotics are quickly and haphazardly administered when a patient does not improve 
health after the initial therapy. Likewise, the probability of encountering a MDR pathogen is enhanced when antimicrobial treatment 
is administered for too long of a time period. As a result of ASPs, these issues can be minimized. 2 Inevitably, lower medical costs are 
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another "bottom-line"1 goal of ASPs without compromising the standard of care administered to the patient. 1 
fn order for an ASP to be effective in achieving the goals described above, it is imperative that appropriate health care profession-
als are actively involved. There can be several combinations of participants that prove to be effective, but the fundamental staffing 
involved in an ASP usually includes an infectious disease physician, clinical pharmacist, and infection control personnel. The ASP 
pharmacist works closely with the microbiology laboratory who provides patient-specific cultures and vital susceptibility informa-
tion.1 An emergency medicine clinical pharmacist (EPh) can play a significant role in an antibiotic stewardship program, by recon-
sidering empiric antimicrobial treatment before the patient leaves the emergency room (since a patient is normally started on an 
IV broad-spectrum antibiotic after arrival in the emergency room before a culture is taken). 10 
Several strategies have been established to create and manage an effective institutional ASP, but there are basic principles that are 
crucial for success. Some common, baseline items that are present in the majority of successful ASPs include educational resources, 
the development of guidelines incorporating both local and national concerns, prior approval, post-prescription review and com-
puter-based decision support. 1 Also, ASPs are most effective when they incorporate local guidelines into national guidelines by 
taking into consideration the prescribing and resistance patterns of antimicrobial agents in a certain region. Two proven strategies 
for incorporating ASPs are the "back-end"2 and "front-end"2 approaches. The "front-end"2 approach includes formulary restriction 
and preauthorization (e.g., phone calls to the stewardship team) for restricted antimicrobial agents. The negative effect of this 
strategy is a possible delay in the administration of "stat" antimicrobials. The "back-end"2 approach, also known as the prospective 
audit, involves the antimicrobial support team, including the infectious disease clinical pharmacist, to give feedback with sugges-
tions to the prescriber based on institutional guidelines, patient specific information and culture results. 2 Common interventions 
include de-escalating or discontinuing one or more medications, switching from an intravenous to oral dosage form, and recom-
mending a short-term duration of therapy. Additional strategies include educational programs, antimicrobial order forms, and 
computer systems with clinical decision support (such as computerized physician order entry). Overall, it is important for each insti-
tution to build an effective ASP based on available resources, personnel and various local factors. 2 
Although many health care settings have success-
fully implemented an ASP, there are a number of 
barriers that may be encountered including a lack 
of fundraising and physician participation, an in-
sufficient number of infectious disease physicians 
and pharmacists, inadequate or absent diagnostic 
facilities, poor data collection, variation in data 
collection, a lack of communication among various 
health care professionals and a lack of coopera-
tion among health care facilities. 8'11 An underlying 
issue that has a prominent role in the lack of phy-
sician participation is that only approximately 18 
percent of infectious disease physicians that par-
ticipate in ASPs are reimbursed for their services. 1 
These sorts of obstacles are especially true for 
smaller institutions with limited budgets and per-
sonnel. In order to overcome these problems, it is 
suggested that executive planning and continued 
education programs be implemented to increase 
the cooperation among health care professionals ________________ _,_ 
to augment their clinical knowledge base dealing 
with steps to decrease and prevent antimicrobial resistance. 11 Therefore, educational programs directed at health care profession-
als can have a significant impact on the awareness of antimicrobial resistance, and the necessary procedures that need to be con-
sidered in their area of practice. 
Impact of ASPs 
There are numerous examples of successful implementation of ASPs to combat certain drug resistant pathogens and to improve 
the quality of patient care in a variety of specific health care settings. For example, an ASP was initiated in 2002 at the Vanderbilt 
University Hospital surgical trauma and intensive care units. The data collected as a result of this ASP spanned over an eight-year 
period. Over this time period, there were 1, 794 Gram negative pathogens isolated. As a result of the initiation of the ASP, the per-
centage of infections due to MDR pathogens decreased from 34.7 percent in 2002 to 8.5 percent in 2008. Because resistant Gram 
negative infections are associated with about three times the health care costs compared to antimicrobial susceptible Gram nega-
tive infections, the implementation of the ASP resulted in decreased overall health care costs. 12 
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Similarly, at John Hopkins Children's Medical and 
Surgical Center, a 175-bed hospital, an antimicrobial 
stewardship campaign was implemented. As a re-
sult, there was an 11.6 percent decrease in the num-
ber of doses of restricted antimicrobial agents dis-
pensed. In addition, there was a 40 percent reduc-
tion in the number of telephone calls from the phar-
macy when restricted antimicrobial use occurred. 
This was in large part due to the increased commu-
nication and educational programs offered to pre-
scribers of the antimicrobial stewardship campaign. 
Additionally, there was a $370,069 decrease in the 
projected costs associated with restricted antimicro-
bial agents. 13 
-----------------------------
A clinical trial evaluated the effectiveness of an ASP 
by comparing an intervention group (a pharmacist 
involved in antimicrobial stewardship) compared to 
a control (no antimicrobial stewardship pharmacist). 
The role of the stewardship pharmacist was to utilize prospective audit for the basis of interventions, to monitor the cultures of the 
patients, and to educate health care personnel of the program. In this study, there were 442 antibiotic orders for 160 patients. A 
total of 168 interventions by the antimicrobial stewardship pharmacist were performed, with a 91 percent acceptance rate by the 
prescribing physician. Compliance of all quality indicators, as a result of the ASP, rose to 54 percent compared to the baseline 16 
percent of the control group. The quality indicators, together forming the primary outcome measure of this study, included docu-
mented indication for antibiotic therapy, appropriate cultures collected, appropriate empirical therapy and antimicrobial selection 
based on institutional and national guidelines, and appropriate de-escalation. 14 
ASPs are currently being implemented in settings beyond the hospital and inpatient facilities in order to incorporate a "full cycle of 
care." An ASP should not end once a patient is discharged, but should transition to the outpatient setting. For example, the Cleve-
land Clinic formed the community-based parenteral anti-infective therapy program (CoPAT). Under this program, an infectious dis-
ease consultation is mandated for any patient that is discharged to another facility or to the patient's home. During this consulta-
tion, infectious disease clinicians review laboratory results and also schedule follow-up appointments. Follow-up visits are thought 
to decrease readmissions, which is a major concern since 34 percent of Medicare patients discharged from hospitals are re-
hospitalized within 90 days, adding an additional $17.4 billion to overall Medicare costs. Demonstrating the importance of the fol-
low-up visits, over one-half of these re-hospitalized patients were not scheduled for a follow-up visit. Overall, the Cleveland Clinic's 
initiative to expand their ASP program beyond their inpatient facility is aimed at improving patient health and is an area of future 
expansion of ASPs. 15 
Conclusion 
Antimicrobial resistance is a major health care-associated pre-
dicament. Without proper preventative measures, such as the 
implementation of ASPs, patient health could be severely 
compromised. Likewise, the use of current antimicrobial 
agents must be monitored in an attempt to prevent resistance 
due to inappropriate prescribing, length of treatment, and 
over-prescribing. ASPs have been proven to be efficacious in a 
variety of formats, especially when institutional guidelines 
based on local patterns are combined with national guide-
lines. Additionally, the involvement of multiple health care 
There are still many barriers in the 
implementation of ASPs that need to be 
overcome in many institutions, but once 
conquered, the impact will continue to 
grow, eventually having an impact 
beyond the inpatient setting. 
professionals, including pharmacists, is an imperative part of ------------------------" 
an ASP improving patient care and decreasing antimicrobial 
resistance. There are still many barriers in the implementation of ASPs that need to be overcome in many institutions, but once 
conquered, the impact will continue to grow, eventually having an impact beyond the inpatient setting. 
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ASK AN EXPERT 
During our research on ASPs, we had the opportunity to interview Jason Pogue, PharmD, BCPS-ID, a clinical pharmacist (infectious 
diseases) at Sinai-Grace Hospital, Detroit Medical Center and author of several leading articles in this area of practice. 16•17 
Q: Why do you think ASPs are important to our health care system? 
JP: Antimicrobial resistance has been recognized by the World Health Organization (WHO} as one of the top three current 
threats to human health. As the antimicrobial pipeline falls further behind the pace of antimicrobial resistance develop-
ment, ASPs become even more vital to health care in order to preserve the antimicrobials we currently have. 
Q: When formulating budget appropriations, do you believe health care institutions consider these developments in 
antimicrobial resistance to be of vital importance? 
JP: Firstly, when strictly focusing on the bottom line, since infections involving multidrug-resistant organisms are so costly, 
antimicrobial resistance is to be avoided at all costs. Recently the government and other payers are not reimbursing treat-
ment of health care-associated infections, leaving the institution to shoulder the financial burden. This makes health care 
facilities carefully consider, develop, and utilize an ASP to combat the development of antimicrobial resistance. Further-
more, drug resistant pathogens often require new, broader spectrum drugs for treatment, which are extremely expensive. 
Therefore, hospitals consider antimicrobial resistance as a priority concern when developing a budget. Even though all 
health care institutions desire to run an effective ASP, since ASPs have been proven to improve patient outcomes and 
lower overall health care costs, the lack of adequate resources needed up front may restrict many institutions from seeing 
the full effect of a complete ASP. 
Q: IDSA has attempted to combat the lack of development In the antimicrobial pipeline by introducing the 10 x '20 
Initiative calling for the development of ten novel antibiotics by the year 2020. Is this realistic? 
JP: Considering the current state of antimicrobial development, this goal is lofty and may be unlikely. Most new antibiotics 
in development are not novel, but rather are more diverse derivatives of current antibiotics since they do not have a new 
mechanistic target. While these derivatives can lower the cost of current treatment, they are not considered novel devel-
opment. 
Currently, the two major antibiotics that work to fight Acinetobacter baumannii are ampicillin-sulbactam and imipenen. 
This microbe, by innate nature, is resistant to many antibiotics. However, it is becoming increasingly resistant to ampicillin-
sulbactam and imipenen. The susceptibility of this organism to the two antibiotics decreased from 89 percent to 40 per-
cent and 99 percent to 42 percent, respectively. Currently, there are not any new drugs to combat this organism, only 
leaving older medications as treatment options, which have an increased number of side effects. For example, colistin can 
be used, but causes nephrotoxicity in 40 percent of the patients. Therefore, many deleterious outcomes can occur due to 
the inability to utilize the first line therapy. Also, as resistance develops, the length of hospital stay and mortality rates 
increase, which highlights the importance of ASPs. 
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Assessment Questions-Antimicrobial Stewardship Programs 
1. Which is NOT a reason for concern dealing with the spread 
of antimicrobial resistance? 
A. Decrease in research and development of antimicro-
bial agents by major pharmaceutical agents 
B. Administration of the correct dose 
C. Over-prescribing antibiotics 
D. Inappropriate and/or prolonged use of broad-
spectrum antimicrobial coverage 
2. All of the following are benefits of successful ASPs EXCEPT: 
A. Decrease in overall health care costs 
B. Ability for institutions to decrease the number of staff 
health care professionals 
C. Improved patient quality of care 
D. Decrease length of hospital stay 
3. The primary goal of an ASP is to: 
A. Decrease overall health care costs 
B. Increase the quality of patient care 
C. Decrease the number of antimicrobial agents needed 
to be stocked in the pharmacy 
D. Increase the need for improved laboratory resources 
and machinery 
4. ASPs encourage all of the following EXCEPT: 
A. Transfer of parenteral treatment to oral treatment 
B. Off-cycle antibiotic prescribing 
C. Streamlining or de-escalating antibiotic therapy 
immediately when appropriate 
D. More than one of the above 
5. Which term correctly describes an event when broad-
spectrum antibiotics are quickly and haphazardly 
administered if a patient does not improve health after 
the initial therapy? 
A. Antibiotic cycling 
B. Spiraling empiricism 
C. Stat treatment 
D. Multi-drug resistant medication therapy 
6. Common participants involved in the operation of a 
successful ASP include all of the following EXCEPT: 
A. Information technology staff 
B. Infectious disease physician 
C. Clinical pharmacist 
D. Physical therapist 
7. Common strategies that are present in successful ASPs 
include all of the following EXCEPT: 
A. Prescription approval 
B. Educational resources for the involved health care 
professionals 
C. Post-prescription review 
D. Exclusive use of national guidelines 
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8. A strategy for incorporating an ASP that includes formulary 
restriction and preauthorization for the use of restricted 
antimicrobial agents is known as: 
A. Front-end approach 
B. Back-end approach 
C. "Stat" approach 
D. Guideline approach 
9. This strategy for incorporating an ASP, also known as the 
prospective audit, utilizes interventions and feedback by an 
infectious disease clinical pharmacist to make suggestions to 
the prescriber: 
A. Front-end approach 
B. Back-end approach 
C. Computerized physician order entry 
D. Formulary restriction/preauthorization 
10. Common barriers facing the implementation of an 
efficacious ASP include all of the following EXCEPT: 
A. Inadequate or absent diagnostic facilities 
B. Communication among health care facilities and 
health care professionals 
C. Poor data collection 
D. Insufficient number of infectious disease physicians 
and pharmacists 
To receive continuing education credit for this program, you 
must answer the above questions and fill out the evaluation 
form. Please visit www.onu.edu/pharmacy to enter the 
required information. Please allow two to three weeks for 
electronic distribution of your continuing education certificate, 
which will be sent to your valid email address in PDF format. 
~1 Ohio Northern University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is eligible for credit until 02/28/15. 
To receive continuing education credit for this program, visit www.onu.edu/pharmacy/CE OR fill out the form below 
including your indicated answers to the assessment questions and return to: 
Office of Continuing Education at the Raabe College of Pharmacy 
Ohio Northern University 
525 South Main Street 
Ada, Ohio 45810 
Program Title: Antimicrobial Stewardship Programs 
UAN: 0048-0000-12-009-H04-P CEUs: 0.1 
All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of 
continuing education credit. Certificates will be distributed as a PDF document to a valid email address. 
Name: 
Address: 
City: State: Zip: 
Phone: E-mail: 
Pharmacy License #: State: ONUAlumnl? y N 
The program objectives were clear. 1 2 3 4 5 
The program met the stated goals and objectives: 
Identify ways in which Antimicrobial Stewardship Programs (ASPs) are 1 2 3 4 5 
utilized to decrease microbial resistance. 
Comprehend the multiple and interconnected roles of various health 1 2 3 4 5 
care professionals associated with ASPs. 
Recognize the significant decrease in current research and development 
of antimicrobial agents by major pharmaceutical companies; and its 1 2 3 4 5 
impact on the need to properly utilize available antibiotics. 
List strategies that can be established to create and run an effective 1 2 3 4 5 institutional ASP. 
Examine how the quality of patient health has been improved as a result of 1 2 3 4 5 
successful implementation of ASPs in a variety of health care settings. 
The program met your educational needs. 1 2 3 4 5 
Content of the program was interesting. 1 2 3 4 5 
Material presented was relevant to my practice. 1 2 3 4 5 
Comment/Suggestions for future programs: 
Thank you! 
Answers to Assessment Questions-Please Circle Your Answer 
1.ABCD 4. A B C D 
2. A B C D 5. A B C D 
3. A B C D 6. ABCD 
Any questions/comments regarding this continuing education program can 
be directed to Lynn Bedford, Advanced Administrative Assistant for the 
Office of Continuing Education (email: l-bedford<@onu.edu, phone 419-
772-1871). 
7. A B C D 10. A B C D 
8. A B C D 
9. A B C D 
~. Ohio Northern University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is eligible for credit until 02/28/15. 
